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Why do people use new psychoactive substances? Development of a new measurement 
tool in six European countries
Abstract
Introduction: New psychoactive substances (NPS) pose a public health threat. Many studies 
have tried to identify the reasons of NPS use, however, none of them have so far used any 
standardised measures. The aim of this study was (I) to develop and cross-culturally validate 
the New Psychoactive Substance Use Motives Measure (NPSMM) and (II) to compare motives 
of NPS use across countries and user types. Methods: Three subgroups (socially marginalised 
users; night life attendees; and members of online communities) of NPS users (N=3023) were 
recruited from six EU-member countries. Demographics, motives and types of NPS used were 
assessed. NPS use motives were measured by adapting the extended six factor version of the 
Marijuana Motives Measure. Results: Exploratory and confirmatory factor analysis resulted in 
a similar five-factor solution across most of the countries: coping, enhancement, social, 
conformity and expansion motives. Marginalized users scored higher on coping and conformity 
motives, night life groups showed higher endorsement of social motive, whereas online 
community users showed higher scores on expansion motives. Various types of NPS were also 
associated with different motives. Conclusion: NPS use motives might be associated with both 
the groups of users and the specific types of NPS being consumed. Expansion (psychedelics) 
and enhancement (stimulants) motives seemed to be linked to the chosen NPS product type, 
while coping, social and conformity motives were rather associated with user groups. NPSMM 
was found to be a valid instrument to measure NPS motives.
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Why do people use new psychoactive substances? Development of a new measurement 
tool in six European countries
INTRODUCTION
In the past two decades, with the appearance of new psychoactive substances (NPS), the 
global drug market has markedly changed. The altered scenario of contemporary substance use 
was characterized by a shift to web based trafficking and information sourcing (Corkery et al., 
2017; Orsolini et al., 2017), which usually predicts real life NPS scenario (Schifano et al., 
2015). With NPS’ diffusion on the web, a rapid increase in the number of these drugs was 
observable as early as the beginning of the 2000s (Schifano et al., 2003). Popularity of NPS can 
mainly be attributed to their easy availability (e.g., online purchase), relatively low price, high 
purity, perceived safety profile or misbeliefs about their safety as well as their temporary legal 
status (e.g., Gittins et al., 2018). Furthermore, NPS became immensely popular in an era in 
which the availability and purity of classic drugs – such as cocaine or heroin – decreased (e.g., 
Zawilska, 2017), therefore users of formerly scheduled substances shifted to NPS consumption. 
Nevertheless, NPS consumers often co-ingest other psychoactive substances, but mostly 
amphetamine-derivatives, cocaine, cannabis and ethanol (Newcombe, 2009; Matthews and 
Bruno, 2010; Winstock et al., 2011; Barratt et al., 2013; Caviness et al., 2015). 
Users of psychoactive substances started to experiment with phenethylamines, 
tryptamines, piperazines or ketamine-type substances. However, synthetic cathinones (e.g., 
mephedrone, methylone, 4-MEC, MDPV or pentedrone) and synthetic cannabinoids (e.g. AM-
or JWH-type products) became the most frequently consumed NPS in both the adult and 
adolescent population. By the end of 2016, over 620 NPS were monitored by the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA), with 66 NPS identified for the 
first time in that year (EMCDDA, 2017a). The later emergence of the misuse of novel synthetic 
opioids (e.g., fentanyl-type substances) created an opioid crisis (especially in the United States), 
with over 66% of total overdose cases related to opioid overuse in 2016 (Stoicea et al., 2016). 
Furthermore, recent data regarding heroin-related fatal overdoses (Vaiano et al., 2019) suggests 
that not only novel synthetic opioids but heroin itself also returned to the drug market as a 
relevant player. With elevating frequencies of NPS intoxications (e.g., Zawilska, 2015), public 
awareness increased about the potential adverse health and social outcomes of recurrent NPS 
consumption. It’s however also important to note that a consolidation in the number of newly 
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introduced NPS may be seen as a novel and decreasing trend in terms of NPS trafficking 
(EMCDDA, 2019). 
There are only a few available studies regarding NPS use prevalence in the general 
population. In England and Wales, the 2010/2011 British Crime Survey identified a 0.6-1.4% 
lifetime mephedrone use (Smith and Flatley, 2011). The National Survey of Drug Use and 
Health assessed a US national representative sample of non-institutionalized individuals 
between 2009 and 2013, and found psychedelic tryptamines (1.1% lifetime prevalence), 
phenethylamines (0.2% lifetime prevalence) and synthetic cannabinoids (0.05% lifetime 
prevalence) the most commonly used NPS (Palamar et al., 2015). The 2015 National Survey 
on Addiction Problems in Hungary found a 1.9%, 1.3% and 0.6% lifetime prevalence rate for 
synthetic cannabinoids, designer stimulants and mephedrone respectively (Paksi et al., 2016). 
A Polish survey conducted in 2015 (N=2052) showed 2.2% lifetime prevalence rate and 0.5% 
last year prevalence rate for NPS use (Public Opinion Research Center, 2015). Based on the 
results of the 2015 Epidemiological Survey of Substance Abuse (ESA) a lifetime NPS use 
prevalence of 2.8% was found in Germany in the general population (EMCDDA, 2017b).
Higher frequencies were observed in specific subpopulations (Orsolini et al., 2019), 
usually assessing non-representative/non-probability convenience samples. Among an 
Australian sample of regular psychostimulant users, lifetime use of mephedrone varied between 
19-23%, whereas 10% was found for methylone and 5% for MDPV in 2012 (Sindicich and 
Burns, 2012). Among patrons of US nightlife scenes, a 8.2% lifetime prevalence of synthetic 
cannabinoid use was identified in 2012 (Kelly et al., 2013). In the Netherlands, among club-
goers and ravers in Amsterdam lifetime prevalence rates were: 19% 2C-B, 15% 4-FA, and 9% 
mephedrone (Nabben, Korf and Benschop, 2014). A 59% of lifetime NPS use was described 
among a Scottish at-risk group (including people in contact with mental health services, people 
affected by homelessness, people who inject drugs or men who have sex with men) in a study 
conducted between 2015 and 2016 (MacLeod et al., 2016). The 2017 Global Drug Survey study 
showed a 5.8% lifetime prevalence of synthetic cannabinoids, 5.1% of 2C-B, 3.7% of DMT 
and 1.9% of mephedrone use (Winstock et al., 2017). In an Italian study assessing a sample of 
adolescents and young adults from both urban and rural areas (Martinotti et al., 2015) 4.7% of 
the respondents reported lifetime NPS use, with mephedrone (3.3%), synthetic cannabinoid 
(1.2%) and Salvia divinorum (0.3%) consumption being identified. A lifetime mephedrone and 
NPS use of 1.1% and 1.5% was identified in a large sample of welsh adolescents (Midgley et 
al., 2018). 
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Intrinsic motives of NPS consumption usually include curiosity, increasing pleasure, 
experimentation, self-exploration and escapism (Bonar et al., 2014; Corazza et al., 2014; 
Orsolini et al., 2015; van Amsterdam et al., 2015; Lauritsen and Rosenberg, 2016; Barnard et 
al., 2017). These reasons are therefore very similar to the explored reasons behind the use of 
other legal or illegal substances. 
Understanding the reasons or motives of why people engage in NPS use is essential for 
the reduction of its use and the related harms that their use may cause. Similarly to other legal 
drugs (Cox & Klinger, 1988), psychological motives of use may represent the final decision 
whether to use different types of NPS or not and therefore they might be the most proximal 
factor for using them. Thus, many studies have already assessed the reasons behind NPS use, 
but so far none of them used any standardized measures. Regarding the exploration of substance 
use motivations, Cooper’s four-factor model (1994) has been used and expanded to study 
alcohol-, cannabis- (Simons et al., 1998) or amphetamine-related motives (Thurn et al., 2017). 
Cooper – within the theoretical framework of Cox and Klinger’s Motivational Model (1988) – 
described four motivational factors for alcohol use: 1) enhancement (i.e. increasing positive 
affect and experience), 2) social (i.e. enhancing sociability and social situations), 3) conformity 
(i.e. avoiding rejection by peers), 4) coping (i.e. reducing negative affect). Simons and 
colleagues (1998) developed the Marijuana Motives Measure (MMM) and amended Cooper’s 
model with an additional fifth factor, named expansion. This factor primarily refers to the 
expansion of experimental awareness. The MMM was later extended with two items, reflecting 
a sixth motive, labelled routine motives (Benschop et al., 2015), consisting of boredom and 
habit. In case of the Amphetamine-Type stimulants Motive Questionnaire (AMQ), a four-factor 
solution was retained (i.e., enhancement, coping, social, and conformity motives) similar to that 
of Cooper’s (Thurn et al., 2017). It would be important to understand the motives that could 
explain the experimentation or regular use of different types of NPS in order to formulate 
appropriate prevention programs. However, for the present and future research, it is necessary 
to develop and test psychometrically appropriate measure of motives. Previous efforts to 
measure NPS use motives (e.g., Kettner et al, 2019; Sutherland et al, 2017; Bonar et al., 2014) 
used mainly binary, yes/no, items to measure a list of motives and did not apply extensive 
psychometric analyses to identify latent factors behind the responses of users. In this study we 
propose that using a five-factor motivation model including enhancement, social, conformity, 
coping and expansion motives provides deeper understanding of the reasons or motives of the 
use of NPS. Furthermore, we also propose that the relative importance of different motives may 
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vary depending on the type of the NPS and the context of the use. NPS are often consumed for 
experiencing pleasure or enjoyment in general, but on the other hand, varying expectancies 
might be linked to the use of specific products (Soussan & Kjellgren 2016). For instance, the 
consumption of hallucinogenic NPS (e.g. 25i-NBOMe, 4-AcO-DMT, 2C-B) is often driven by 
the need of self-exploration or spiritual attainment. Synthetic cathinones’ expected effects 
include increased self-esteem, sociability, empathy or energy (e.g. Winstock et al., 2011; Karila 
et al., 2015), which may be linked to mainly recreational purposes. Desired effects of synthetic 
cannabinoids consist of euphoria, increased creativity or relaxation and well-being (e.g. 
Spaderna et al., 2013). Tryptamines – like DMT (N,N-dimethyltryptamine), DPT (N,N-
dipropyltryptamine) or 5-MeO-DiPT (1-methyl-5-methoxy-diisopropyltryptamine) – are 
usually chosen by those who seek psychedelic sensations, while piperazines – such as mCPP 
(m-chlorophenylpiperazine), BZP (n-benzylpiperazine) or TFMPP (1-(3-
trifluoromethylphenyl)piperazine) – produce increased energy and euphoria or mild 
hallucinations (Schifano et al., 2015). 
The objective of this paper is twofold. The first aim was to develop the New 
Psychoactive Substance Use Motives Measure (NPSMM) for a cross-cultural application. 
Therefore, beside the development of the NPSMM, the measurement invariance of its various 
language versions should be also tested if it is used in various countries. The second aim was 
to compare the motivational background of the use of NPS across countries and different types 
of users. 
METHODS
Participants and procedure
The study was implemented within the confines of a transnational, interdisciplinary 
research project, funded by the EU. Researchers from six EU-member countries participated in 
the study: Germany, Hungary, Ireland, the Netherlands, Poland and Portugal. A survey was 
conducted between April and November 2016 among altogether 3023 NPS users. Eligibility 
criteria were as follows: 1) recent NPS use (at least once in the past 12 months); 2) being 
resident of the participating country; 3) an age of 18 years or older. 
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The sample consisted of three subgroups: 1) Socially marginalised users, recruited on 
the street or through care and treatment facilities (such as drug services or shelters) as well as 
by using snowball sampling, approached face-to-face by trained fieldworkers or care 
professionals. A pen-and-paper form of the questionnaire was administered by the interviewers 
in most of the cases. 2) Night life attendees were recruited on-site at clubs, rave parties or 
festivals. These respondents were also approached face-to-face, and self-completed either a 
pen-and-paper or an online form of the questionnaire, that they could access through a link 
presented at a flyer, which was distributed to them. 3) Members of online communities were 
recruited via online messages, through drug-related social media sites and internet forums. 
These participants exclusively filled in the online form of the questionnaire. 
The applied questionnaire contained items that measured demographics, routes, motives 
and frequencies of NPS use, problems related to it, ways of NPS obtainment and possible 
perceived ways of tackling NPS problems. Five categories of NPS products were included in 
the study based on their epidemiological and clinical relevance: i.e. herbal blends (e.g. “Spice”)’ 
and/or synthetic cannabinoids; branded (e.g. “bath salts”)’ and/or pure stimulants (e.g. 
mephedrone, MDPV, a-PVP); psychedelics (e.g. NBOMe-x, 2C-x); dissociatives (e.g. 
methoxetamine); and ‘other’ (mainly opioid and benzodiazepine analogues).   
To examine motives for NPS use, a 23-item adaptation of the Marijuana Motives 
Measure (MMM) (Simons et al., 1998) was included in the questionnaire (see table 1). Each 
item has a five-point response option (1= almost never/never, 2= sometimes, 3= half of the 
time, 4= most of the time, and 5= almost always/always). Two items from the original MMM 
(‘So that others won't kid me’ and ‘Because my friends pressure me to’) were omitted because 
they showed little to no validity in previous studies (Chabrol et al., 2005; Zvolensky et al., 2007; 
Benschop et al., 2015) and were thought to be irrelevant in case of adult respondents. 
The detailed data collection process and study methodology (including the translation 
protocol and the exclusion criteria and process) are available elsewhere (Benschop et al., 2017; 
Korf et al., 2018; Van Hout et al., 2017).    
Statistical analysis plan
Exploratory and confirmatory analyses were performed with Mplus 8.0 (Muthén & Muthén, 
1998-2017). Weighted Least Squares Mean and Variance adjusted (WLSMV) estimation 
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method was used (Brown, 2006; Finney & DiStefano, 2006). The items were treated as ordinal 
indicators. The analyses were based on WLSMV estimation which utilizes the entire weight 
matrix to compute S.E. for the parameters, but this method avoids the matrix inversion (Finney 
& Di Stefano, 2006). Missing values were treated with full maximum likelihood function 
implemented in Mplus.
The first step was to test the original factor structure of the motive scale, however the degree of 
fit was unsatisfactory in all countries. The second step was to explore the factor structure in 
each country separately with exploratory factor analysis, and to identify replicable factor 
structure and to select items regarding high factor loading (0.50) on a relevant factor and low 
cross-loadings (<0.30) on other factors. The third step was to test the factor structure within 
confirmatory factor analysis (CFA) framework which included separate CFA analysis on each 
country data, and testing the measurement invariance across countries in order to support cross-
countries comparisons. Invariance of the measurement model across countries was tested using 
the series of analyses. Equality constraints were set during a progression of analyses focusing 
on the factor structure (configural invariance), factor loadings (metric invariance), and 
thresholds (scalar invariance). Invariance was evaluated by a χ2 test of difference between 
nested models, in addition to changes in RMSEA and CFI. 
In the CFA the satisfactory degree of fit requires the comparative fit index (CFI) to be larger 
than 0.95, the Tucker-Lewis Index (TLI) to be close to or larger than 0.95. The third fit index 
applied in this study was root mean square error approximation (RMSEA). RMSEA below 0.05 
indicates excellent fit, the value around 0.08 indicates adequate fit, and value above 0.10 
specifies poor fit. 
As the fourth step, factor scores were calculated for further analyses including comparison of 
factor scores in three groups, namely marginalized users, nightlife users and online community 
users in each country. 
Finally, as the fifth step we estimated the association between the use of specific product 
categories and dimensions of motives with CFA with covariates. The CFA with covariates 
technique was chosen for the present study because it can estimate the effect of several grouping 
variables such as the use of specific NPS product type, multiple use and marginalized status on 
latent variables at the same time. 
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RESULTS
Descriptive statistics
The descriptive statistics of the user samples from the six different countries are presented in 
Table 2. The samples differed in age and gender composition. The mean age of the samples 
varied between 23 and 33. In four countries, more than 70% of the respondents were male. The 
proportion of the three user groups also differed significantly across countries. Usually the 
online community was the largest, with the exception of Ireland and Portugal. The samples are 
heterogeneous also in terms of types of NPS used, which may reflect the differences in country-
level context of new psychoactive substance use. However, it is important to note that multiple 
use was frequent in all countries with the exception of Ireland. This might be attributed to 
Ireland’s low respondent rate regarding the nightlife subgroup. 
Exploratory Factor Analysis
We tested the original five factor structure across countries, but the degree of fit was 
unsatisfactory in all countries (for interested readers see Supplement 1), therefore exploratory 
factor analysis was applied to identify the appropriate measurement model. We performed 
exploratory factor analysis (EFA) on each country data in which we treated the indicators as 
ordinal scale, therefore the estimation method was WLSMV and rotation was an oblique type 
(GEOMIN) (Yates, 1987). In order to find the number of factors to extract, we also considered 
eigenvalues, fit indices and interpretability of factor solutions. Eigenvalues of factors in each 
sample are presented in Supplement 2. Finally a five-factor solution was selected in all 
countries. Factor loadings are presented in Table 3. The five-factor models were similar in four 
countries, however one country (Portugal) shared four factors with other countries, and one 
factor was not interpretable. 
Confirmatory factor analyses and the test of measurement invariance across countries
In order to test the measurement invariance across countries we performed a series of CFAs 
using the measurement model developed with EFA. The main goal here was to test the 
measurement invariance which also included the separate test of model fit in each countries, 
and also multigroup analyses with increasing constraints. From these analyses we excluded the 
sample from Ireland due to its small size. The separate test of model fit in each of the remaining 
five countries revealed that CFI and TLI were above or close to the optimal value of 0.95 in all 
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countries with the exception of Portugal. In this latter sample the estimation was found not 
trustworthy due to non-positive definite matrix, therefore we excluded it from further analysis. 
The source of severe linear dependencies in the Portuguese sample might be explained by the 
extreme floor effects in some items. RMSEA values were in the acceptable range in three 
countries, but in Polish sample it was above the cut-off value of 0.10. Inspecting the 
modification indices revealed that the freeing the error covariance between item 11 [Because it 
helps me enjoy a party] and item 19 [Because it improves parties and celebrations] improved 
the model in all countries (see Table 4). The error covariance reflects the similarity in content 
of these two items. Factor loadings in each country are represented in Table 5. The final 
questionnaire is presented in the Appendix.
The measurement invariance (equal latent form, equal factor loadings, equal indicator 
threshold), across countries was examined by use of multiple group CFA. Three nested models 
with increasing constraints were estimated. The fit indices are reported in Table 4. First, the 
measurement model was estimated freely in countries together. This unconstrained solution 
fitted the data satisfactorily. In the second model, the factor loadings were set as equal among 
countries, this model could not be identified. Finally, we estimated the model with equal factor 
loadings and equal threshold, the data did satisfactorily fit, however the degree of fit decreased 
significantly compared to the unconstrained solution. Beside the significant Δχ² test, Cheung 
and Rensvold (2002) recommended to consider the change in CFI and RMSEA. The 
hypothesized invariance should only be rejected if ΔCFI is equal to or larger than 0.010, and/or 
ΔRMSEA is equal to or larger than 0.015 (Cheung & Rensvold, 2002; Dimitrov, 2010). During 
the procedure, while estimating configural invariance, the Dutch sample yielded a nonpositive 
definit matrix, therefore it was excluded from the multigroup analysis. Thus data from three 
countries – Germany, Hungary and Poland – were included in the further multigroup analysis. 
Although the Δχ² test turned out to be significant, the changes in CFI and RMSEA were smaller 
than the cut-offs in testing metric and scalar invariance. Therefore the series of multigroup 
analyses supported the configural, metric and scalar invariance across three countries. Hence 
factor scores and latent means are directly comparable in three countries.
Comparison of different users across motives
Applying factor scores resulting from the measurement model, we compared the users across 
the three user types (marginalized users, nightlife users and online community users). Table 6 
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presents the factor scores across the types of users and countries. Two countries are not 
represented in the table: Ireland was excluded due to the small sample size which would make 
any estimation imprecise, Portugal was excluded because the data yielded a different factor 
structure than the data from other countries. 
In order to decrease family wise type I error, we focus only on Bonferroni corrected significance 
level of ANOVA F-value. Further post hoc test was performed when the α value of ANOVA 
omnibus test is lower than .0025. Marginalized users showed higher endorsement in coping 
motive and lower endorsement of expansion motive compared to other user groups in all three 
countries. In night life users, social motive was the strongest motive in three countries 
(Germany, Hungary and Poland). In case of online community users, the results are more 
mixed. In Hungary and Poland, this user group scored higher on expansion motive, however in 
Germany nightlife and online community users did not differ on this motive but scored higher 
than the marginalized group. Contrasted with other countries, in the Netherlands the online 
community sample scored lower on the expansion motive than the nightlife sample.
Construct validity of motives scale – CFA with covariates
We estimated the association between the NPS types and motives in a CFA with covariates 
model. In the model the self-reported use of different NPS categories were the explanatory 
variables and motive factors as latent variables were the explained variable, whereas user types 
(marginalized users versus night life and online community users) were entered as covariates. 
The unstandardized regression coefficients are reported in Table 7. In order to control for 
multiple use, we also entered the indicator variable of multiple use as well. Each NPS type 
yielded a specific pattern of associations with motives. Synthetic cannabinoid use was 
associated with stronger endorsement of coping motive and weaker endorsement of 
enhancement and social motives. The negative coefficients here show that those people who 
indicated synthetic cannabinoid use scored lower on enhancement and social motives than those 
who indicated the use of other types of product. Conformity and expansion motives were not 
related with synthetic cannabinoid use compared to other products. NPS stimulant use was 
associated with higher endorsement of enhancement and social motives and lower endorsement 
of expansion motive. Psychedelics use was strongly linked with higher expansion motive and 
lower degree of coping, social and conformity motives. The use of dissociatives was linked 
with higher coping and expansion motives. Marginalized users scored higher on coping and 
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conformity motives and lower on enhancement, social and expansion motives compared to non-
marginalized users. 
DISCUSSION
The current study assessed the psychometric properties of a new instrument to measure 
NPS use motives and found a factor structure similar to Simons and colleagues (1998) for 
cannabis. Good model fit indices were found across countries and subgroups, even if certain 
countries had to be excluded from the analysis. Construct validity of NPSMM was proven to 
be acceptable. 
Our finding that the use of stimulant emphathogens is associated with higher levels of 
enhancement and social motives is in line with former findings emphasizing that empathogen-
type psychostimulants – usually consumed within the ‘recreational scene’ – are expected to 
increase sociability, feelings of friendliness or playfulness (e.g. Bedi et al., 2010). The use of 
psychedelics was linked with a higher score on the expansion motive. This result might be 
explained by the pharmacodynamical properties and subjective effects of psychedelics, 
characteristically eventuated in unconstrained cognition or a sense of expanded awareness, 
which was recently interpreted within the framework of the integrated information theory (IIT) 
by Gallimore (2015). Expansion was also associated with the use of dissociative NPS as well 
as a higher endorsement of the coping motive. Dissociative NPS, just like classic psychedelics, 
might be able to provide mind-altered experiences for their users, however, some novel 
dissociative drugs – such as 3-MeO-PCP – as compared to traditional psychedelics, may induce 
more severe intoxication and even lethal overdose (Johansson et al., 2017). The coping motive 
is usually associated with higher level of stress and anxiety (Armeli et al., 2014; Buckner et al., 
2014), higher frequency (Thurn et al., 2017) or severity (Vinci et al., 2016) of substance use. 
Based on these findings, we might consider some of the explored motives (e.g. expansion, social 
or enhancement motives) as expectations regarding the effects of the consumed NPS. 
Regarding the association between NPS use motives and different user groups, it may 
be unsurprising that marginalized users showed higher endorsement in coping motive, as low-
socioeconomic background has already been linked to higher coping motive (Stapinski et al., 
2016). Nonetheless, our results also indicate that marginalization should be considered as a 
robust, cross-cultural factor behind instrumental substance use. Among the group of nightlife 
users, social motive was found to be the most dominant motive, showing cultural overlaps, 
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especially when compared with the other two user groups. As club goers often seek the 
experience of shared moments and togetherness (e.g. Hunt et al., 2009), NPS – and particularly 
stimulant NPS – use may serve as a facilitator of enhanced sociability. The result that within 
the online community users’ samples higher expansion motive was identified (in Hungary and 
Poland), can be explained by the characteristics of this specific subsample, namely that many 
of these participants could have been labeled as psychonauts. As former studies highlighted, 
psychonauts are mainly interested in exploring the effects of psychoactive substances (e.g. 
Zawilska, 2017), including the experience of an altered state of consciousness. The motivation 
to expand their awareness therefore can be interpreted as a subgroup-related specificity as well. 
Similarly, the result that social motivation is more relevant in the nightlife group than in the 
online community is far from being surprising as club goers tend to consume psychoactive 
drugs to increase their sociability (e.g. Soussan and Kjellgren, 2016). Nonetheless, the cross-
national variability in the pattern of NPS use motives is also worth mentioning (e.g. the online 
community showed lower expansion scores than the night life group in only Germany and the 
Netherlands). This variability indicat s that the association between NPS motives and specific 
user groups cannot be interpreted as a generally applicable tendency across all countries. 
According to the findings of former studies that assessed potential cross-cultural disparities in 
the pattern of substance use motives, slight differences might occur as a result of cultural values. 
For instance, as Mackinnon and colleagues (2017) pointed out, a significant interaction can be 
expected between drinking motives and dominant cultural values: i.e. respondents from 
individualistic cultures may more strongly endorse social and enhancement drinking motives 
as compared to participants from collectivistic countries. 
When NPS product types and user groups were both entered in the CFA model to assess 
the controlled effect of these grouping variables in connection with the distinct motives, we 
found that the variability of coping and social motives were primarily explained by the 
membership of the marginalized group. Marginalized individuals showed high coping and low 
social motives to consume NPS. As these respondents were socially isolated, it is 
understandable that their main motive was not to increase their sociability or enhance social 
gatherings with substance use. The enhancement motive was mainly associated with stimulant 
use. These findings may be indicative of a mixed influence of the chosen NPS product type and 
the subcultural or socioeconomic background of the respondents with regard to the dominance 
of specific NPS consumption motives. Homeless and marginalized individuals might be 
characterized by higher odds of instrumental substance use in order to escape from their 
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everyday problems and may choose NPS with the lowest price, i.e. herbal blends. Out of the 
five assessed motives, expansion (psychedelics) and enhancement (stimulants) seemed to be 
linked to the chosen NPS product type, while the coping, social and conformity motives were 
rather associated with the user groups. Considerable cross-national differences in the use of 
various NPS products might have resulted from varying rates of the assessed subgroups across 
different countries. For instance, the relatively high number of psychedelic and dissociative 
NPS consumers identified in Germany may primarily be explained by the high proportion of 
online respondents from the same country who usually experience with mind-altering effects 
of novel psychedelics and dissociatives. Available epidemiological studies do not indicate 
major differences in national-level NPS consumption rates between the participating countries 
that might explain the aforementioned cross-national disparities.  
Limitations
Our study relied on the retrospective recall of certain motives, therefore memory bias 
could have been the source of a potential confounding effect. Recruitment bias might have 
occurred during data collection, especially in case of online sampling, while many respondents 
might have limited knowledge or false information about the specific NPS they consumed. This 
might have led to reporting bias in certain cases. Most of the assessed samples consisted of 
mainly male respondents. In order to properly explore potential gender differences in NPS use 
motives, future studies need to assess more balanced samples when it comes to gender 
distribution. For instance, the study by Orsolini and colleagues (2015) already emphasized 
gender differences in NPS intake.  An argument may arise whether or not NPS use in general 
significantly differ from other types of substance use in terms of motivation. Nevertheless, our 
analysis indicated that the consumption of different NPS – such as synthetic cannabinoids, 
branded stimulants or empathogens/nootropics – may be associated with specific patterns of 
motives, therefore NPSMM might be used as a valid motivation measurement tool in case of 
specific subtypes of NPS use as well. As such, it might be redundant to develop distinct 
motivation questionnaires for synthetic cannabinoids, synthetic cathinones or other NPS 
products consumption per se. Construct validity of the motives scales were tested and found to 
be acceptable, however, further measures of validity (e.g. concurrent and convergent) still needs 
testing regarding NPSMM scales. Finally, another limitation of this study lies in the fact that it 
assessed only intrinsic motives but no external factors that might be as well important in case 
of NPS consumption (such as low price or easy availability). 
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CONCLUSIONS
NPSMM can be used to assess the motivational background of the use of various NPS 
within different sociocultural context and socioeconomic heterogeneity. The factor structure of 
NPSMM was confirmed in four out of six countries, however the measurement invariance was 
demonstrated only in three countries. The utilization of NPSMM in further studies might 
contribute to the understanding of why people use certain types of NPS. In addition, NPSMM 
is currently the only validated tool to assess NPS use related intrinsic motives. Its applicability 
in explaining either the frequency or severity of NPS use needs to be tested in the future, within 
the context of both clinical and non-clinical settings.
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Table 1. The original 23-items questionnaire to measure the motives of new psychoactive substance use 
No1 No2
9 16  To be liked Conformity
12 22  To fit in with the group I like Conformity
20 25  So I won't feel left out Conformity
1 1  To forget my worries Coping
6 2  To cheer me up when I am in a bad mood Coping
17 4  To forget about my problems Coping
4 8  Because it helps me when I feel depressed or nervous Coping
7 5  Because I like the feeling Enhancement
13 7  Because it gives me a pleasant feeling Enhancement
18 10  Because it's fun Enhancement
10 12  To get high Enhancement
9 30  Because it's exciting Enhancement
21 9  To know myself better Expansion
24 23  To expand my awareness Expansion
22 26  Because it helps me to be more creative and original Expansion
23 28  To understand things differently Expansion
25 29  To be more open to experiences Expansion
3 11  Because it helps me enjoy a party Social
5 13  To be sociable Social
11 17  Because it makes social gatherings more fun Social
14 19  Because it improves parties and celebrations Social
15 21  Because I feel more self-confident and sure of myself Social
6 31  To celebrate a special occasion with friends Social
Notes: 1Original MMM item number; 2item number used in the current study
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Table 2. Descriptive statistics of participating countries. 
Germany Hungary Ireland Netherlands Poland Portugal χ²/F (p)
N 663 272 62 1190 596 240
Age, Mean (SD) 25.17 
(7.31)
28.49 
(8.51)
32.76 
(6.84) 23.01 (4.54) 25.21 (7.19)
26.99 
(6.49)
60.9 
(p<.001)
Gender, N (%) of men 571 (87.2) 201 (75.3) 36 (58.1) 591 (50.0) 472 (80.1) 174 (72.8) 340.9 
(p<.001)
User types
Marginalized user N (%) 23 (3.5) 101 (37.1) 48 (77.4) 1 (0.1) 86 (14.4) 7 (2.9)
Night life users N (%) 98 (14.8) 15 (5.5) 3 (4.8) 189 (15.9) 172 (28.9) 170 (70.8)
Online community users N (%) 542 (81.7) 156 (57.4) 11 (17.7) 1000 (84.0) 338 (56.7) 63 (26.3)
1253.0 
(p<.001)
Last 12-month use
Herbal blends and/or Synthetic 
cannabinoids N (%)
276 (41.6) 188 (69.1) 17 (27.4) 122 (10.3) 325 (54.5) 61 (25.4) 595.9
(p<.001)
Branded and or pure stimulants 
N (%)
262 (39.5) 178 (65.4) 35 (56.5) 1148 (96.5) 436 (73.2) 64 (26.7) 920.0
(p<.001)
Psychedelics N (%) 425 (64.1) 43 (15.8) 6 (9.7) 393 (33.0) 167 (28.0) 181 (75.4) 435.0
(p<.001)
Dissociatives N (%) 156 (23.5) 50 (18.4) 3 (4.8) 100 (8.4) 95 (15.9) 36 (15.0) 88.0
(p<.001)
Other NPS N (%) 228 (34.4) 76 (27.9) 16 (25.8) 277 (23.3) 139 (23.3) 93 (38.8) 47.1
(p<.001)
Multiple use* N (%) 368 (55.5) 156 (57.4) 13 (21.0) 583 (49.0) 319 (53.5) 127 (52.9) 35.2
(p<.001)
Notes: *More than one product type was mentioned. 
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Table 3. Exploratory factor analyses of motive items in five countries. 
No1 No2 Coping Enhancement Social Conformity Expansion Portugal 
(not 
defined)
GER HUN NED POL POR GER HUN NED POL POR GER HUN NED POL POR GER HUN NED POL POR GER HUN NED POL POR
1 1 .97 .96 .91 .94 .93 .00 -.12 .13 -.03 .04 -.02 -.01 -.03 -.04  -.03 -.04 .01 .01 .07 -.03 -.04 .01 -.01 -.01 .01
17 4 .95 .97 .95 .99 .89 .00 -.05 .12 -.01 .01 .02 .01 -.02 .01  -.04 -.02 .01 -.04 .14 -.02 -.01 -.02 -.01 .00 .04
6 2 .87 .78 .82 .81 .55 .04 .05 -.01 .20 .17 .06 .06 .07 .00  .03 .03 .05 .03 -.04 -.04 .02 .02 -.02 -.08 -.35
4 8 .85 .66 .73 .68 .67 .10 .18 -.04 .30 -.06 -.07 -.17 .04 -.06  .05 .10 .17 .14 -.07 .11 .19 .06 .01 .05 -.53
7 5 .03 -.02 .25 -.01 .08 .91 .92 .87 .76 .55 .01 .00 -.02 .23  -.02 .05 -.01 -.01 -.56 -.03 .06 -.02 .08 .20 .00
13 7 .08 .04 .07 .00 .08 .88 .81 .91 .78 .66 -.03 .12 .04 .30  .04 -.02 .01 .02 -.43 -.01 .01 -.05 -.03 .13 .03
23 28 .06 .07 .07 .08 -.10 .08 .11 -.03 -.02 .05 -.14 -.07 -.04 -.03  -.03 -.05 -.08 -.09 .04 .88 .86 .94 .92 .92 .01
24 23 .00 .12 .11 -.08 .00 -.04 -.01 -.02 -.04 -.04 .17 .02 -.10 .03  -.35 .40 .00 .03 -.02 .88 .14 .81 .89 .85 .35
25 29 -.03 -.13 -.05 .02 -.04 .10 -.04 .06 .04 .21 -.10 .03 .00 .04  .08 .17 .07 .23 .00 .87 .87 .84 .74 .61 -.09
21 9 -.02 .01 .25 -.04 .11 -.07 -.04 -.05 -.01 -.10 .06 .05 -.08 -.02  -.22 .03 -.06 .02 .00 .81 .73 .72 .87 .74 .09
22 26 .25 .05 .19 -.01 .24 -.01 .09 -.09 .10 .05 -.01 -.01 .06 -.04  .03 .29 .02 .33 -.02 .67 .54 .66 .53 .52 -.12
9 30 -.01 .00 -.13 .08 .00 .35 .19 .11 .32 .86 .11 .31 .06 .36  .09 -.03 .22 .00 -.02 .53 .50 .58 .36 -.03 .47
3 11 .09 .03 .07 .03 -.01 -.05 .30 .08 .01 .77 .93 .88 .79 .92  .00 -.03 .01 .03 .08 -.03 -.07 -.10 -.10 -.01 .12
14 19 .03 -.03 -.01 -.01 -.07 .01 .20 -.02 -.02 .79 .92 .76 .94 .86  .06 .10 -.07 .21 .21 -.02 -.06 -.05 -.09 -.04 -.03
6 31 -.08 .05 -.11 .08 .11 .15 .03 .10 .06 .63 .51 .59 .23 .54  .28 .10 .15 .11 .00 .15 .17 .50 .04 -.08 -.04
11 17 -.01 -.14 .07 -.07 -.11 .14 -.12 .05 -.07 .86 .47 .51 .52 .49  .40 .44 .22 .49 .24 .05 .09 .13 .03 .00 -.03
10 12 .11 .08 .15 .34 -.01 .36 .25 .19 .19 .54 .34 .35 .19 .23  -.04 .00 .06 -.11 .04 -.21 .26 .28 .04 -.07 .07
20 25 .38 -.01 .16 .41 .37 -.04 .08 .06 -.13 -.08 -.04 -.24 -.25 .07  .74 .87 .82 .47 .72 .04 -.04 .02 .04 -.13 .11
12 22 .28 .00 -.08 .03 .02 -.03 .02 -.01 .07 .15 .07 -.03 -.04 .00  .70 1.01 .95 .87 .94 -.10 -.32 -.05 -.03 .03 -.09
9 16 .36 .09 .25 .26 .25 -.08 -.17 -.16 -.16 -.01 .03 .06 .14 .05  .69 .77 .65 .65 .95 -.03 .00 .01 .00 .07 .07
5 13 -.03 -.02 -.04 .00 .28 .18 -.08 .27 .03 .33 .29 .37 .35 .09  .41 .45 .16 .72 .30 -.01 .22 .15 .15 .06 -.13
15 21 .46 .17 .22 .02 .35 .00 .10 -.05 .25 .23 .22 .09 .27 -.07  .35 .64 .48 .86 .45 .07 .09 .03 -.02 .22 -.12
18 10 -.16 -.03 -.10 -.09 .00 .63 .36 .68 .26 .86 .28 .65 .23 .71  -.05 -.01 -.03 -.03 -.09 .09 .03 .13 .10 .03 .63
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Table 4. Model fit and multigroup analyses
χ² df CFI TLI RMSEA Cfit of 
RMSEA
Δχ² Δdf ΔCFI ΔRMSEA
Confirmatory factor analysis in countries
Germany 388 94 0.983 0.979 0.069 <0.001
Hungary 247 94 0.968 0.959 0.079 <0.001
Netherlands 673 94 0.960 0.949 0.072 <0.001
Poland 667 94 0.963 0.953 0.102 <0.001
Portugal#
Germany* 337 93 0.986 0.982 0.063 0.001
Hungary* 238 93 0.970 0.961 0.077 <0.001
Netherlands* 497 93 0.972 0.964 0.061 <0.001
Poland* 585 93 0.968 0.959 0.095 <0.001
Portugal#
Ireland###
Multigroup analyses including (Germany. Hungary. Poland)##
Configural 
invariance 
1125 279 0.978 0.971 0.077 <0.001
Metric invariance 1244 301 0.975 0.970 0.079 <0.001
Metric against 
configural 
invariance
158 22 0.003 0.002
Scalar invariance 1536 387 0.970 0.972 0.077 <0.001
Scalar against 
metric invariance
360 86 0.005 -0.002
Notes: *: Applying error covariancies between item 11 and item 19. Configural invariance – 
unconstrained model. Metric invariance –factor loadings are constrained. Scalar invariance – 
thresholds and factor loadings are constrained. #: the latent covariance matrix is not positive 
definit therefore the estimation is not trustworthy in Portugal sample. We did not use data 
from Portugal in the multigroup analyses. ##: In the multigroup analysis the Netherlands 
sample yielded nonpositive definit matrix, therefore it was excluded from the multigroup 
analysis. ###: Ireland was excluded from this step of analysis due to the low sample size.
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Table 5. Confirmatory factor analyses in each countries: standardized factor loadings
No1 No2 Coping Enhancement Social Conformity Expansion
GER HUN NED POL GER HUN NED POL GER HUN NED POL GER HUN NED POL GER HUN NED POL
1 1 0.95 0.90 0.92 0.93
17 4 0.91 0.79 0.86 0.86
6 2 0.94 0.95 0.94 0.96
4 8 0.85 0.83 0.85 0.82
7 5 0.86 0.93 0.93 0.87
13 7 0.93 0.86 0.87 0.90
3 11 0.71 0.72 0.56 0.66
11 17 0.86 0.78 0.95 0.91
14 19 0.75 0.71 0.56 0.80
9 16 0.90 0.85 0.89 0.78
12 22 0.86 0.85 0.75 0.85
20 25 0.95 0.81 0.86 0.80
21 9 0.75 0.73 0.78 0.79
22 26 0.65 0.79 0.77 0.74
23 28 0.87 0.85 0.92 0.83
25 29 0.89 0.88 0.84 0.88
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Table 6. Comparison of factors scores among different type of users in each countries. 
Countries Motives MarginalizedMean
Night life
Mean
Internet
Mean F p
coping 1.03a 0.57b -0.01c 49.40 <.001
enhancement -0.14 0.12 -0.10 4.55 .011
social 0.07a 0.48b -0.07a 35.96 <.001
conformity 0.93a 0.73a -0.01b 78.77 <.001
Germany
expansion -0.55a 0.02b 0.00b 8.04 <.001
coping 0.47a -0.37b -0.19b 27.72 <.001
enhancement -0.10 -0.04 -0.01 0.43 .649
social -0.31a 0.52b 0.17b 27.91 <.001
conformity 0.15 0.37 0.07 1.92 .148
Hungary
expansion -0.07a -0.29a 0.13b 5.22 .006
coping 0.22 0.17 1.04 .308
enhancement -0.27a -0.07b 13.76 <.001
social -0.03 0.02 2.17 .141
conformity 0.20 0.14 1.46 .228
Netherlands
expansion 0.22a 0.04b 13.50 <.001
coping 0.58a -0.06b 0.00b 23.56 <.001
enhancement -0.15 -0.05 0.04 2.58 .077
social -0.27a 0.16b 0.01c 16.20 <.001
conformity 0.09 0.12 0.02 1.41 .244
Poland
expansion -0.25a -0.11a 0.17b 19.32 <.001
Notes: The factor scores and means of each country were calculated separately. Factor scores 
are standardized values (Mean=0; SD=1). F values which are significant after Bonferroni 
correction (p<.0025) are boldfaced. Means sharing a common subscript are not statistically 
different at α=.05 according to Games-Howell test. 
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Table 7. Concurrent predictors of motives: CFA with covariates analyses. 
Coping Enhancement Social Conformity Expansion
Product types
Herbal blends and/or 
Synthetic cannabinoids
0.45***
(0.06)
-0.29***
(0.07)
-0.30***
0.06
0.21**
0.08
0.01
(0.06)
Branded and or pure 
stimulants
-0.10
(0.07)
0.36***
(0.07)
0.67***
0.07
0.06
0.09
-0.56***
(0.06)
Psychedelics -0.18**
(0.06)
0.06
(0.07)
-0.14*
0.07
-0.20*
0.08
0.68***
(0.06)
Dissociatives 0.33***
(0.07)
-0.03
(0.07)
-0.07
0.08
0.17
0.09
0.25***
(0.07)
Other NPS 0.27***
(0.06)
0.11
(0.07)
0.07
0.07
-0.03
0.08
0.14*
(0.06)
Multiple use 0.06
(0.08)
0.14
(0.08)
0.12
0.08
0.06
0.10
0.10
(0.07)
Marginalized users 1.35***
(0.07)
-0.31***
(0.08)
-0.96***
0.08
0.83***
0.09
-0.20**
(0.07)
R² 21.9% 7.7% 18.9% 8.6% 19.9%
Notes: N=2761. In this analysis the data from Germany, Hungary, Ireland, Netherlands and Poland are 
included. The table represents unstandardized regression coefficients with standard errors. 
*:p<.05; **:p<0.01; ***: p<.001.
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APPENDIX
The New Psychoactive Substance Use Motives Questionnaire (NPSMQ)
Thinking now of all the times you have used new psychoactive substances in the past year, 
how often you have uses these substances for the following reasons? 
Never/ 
almost 
never
Some 
of 
the 
time
About 
half 
of the 
time
Most 
of 
the 
time
Almost 
always/ 
always
1  To forget my worries 1 2 3 4 5
2  Because I like the feeling 1 2 3 4 5
3  Because it helps me enjoy a party 1 2 3 4 5
4  To be liked 1 2 3 4 5
5  To know myself better 1 2 3 4 5
6  To cheer me up when I am in a bad mood 1 2 3 4 5
7  Because it gives me a pleasant feeling 1 2 3 4 5
8  Because it makes social gatherings more fun 1 2 3 4 5
9  To fit in with the group I like 1 2 3 4 5
10  Because it helps me to be more creative and 
original
1 2 3 4 5
11  To forget about my problems 1 2 3 4 5
12  Because it improves parties and celebrations 1 2 3 4 5
13  So I won't feel left out 1 2 3 4 5
14  To understand things differently 1 2 3 4 5
15  Because it helps me when I feel depressed or 
nervous
1 2 3 4 5
16  To be more open to experiences 1 2 3 4 5
Coping: 1, 6, 11, 15
Enhancement: 2, 7
Social: 3, 8, 12
Conformity: 4, 9, 13
Expansion: 5, 10, 14, 16
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SUPPLEMENTS
Supplement 1. The degree of fit of the original model. 
χ² df CFI TLI RMSEA Cfit of 
RMSEA
Germany 2034 220 0.911 0.898 0.112 <0.001
Hungary 875 220 0.890 0.873 0.106 <0.001
Ireland 435 220 0.874 0.855 0.128 <0.001
Netherlands 3402 220 0.845 0.822 0.110 <0.001
Poland 2235 220 0.891 0.874 0.124 <0.001
Portugal*
Notes: *: the latent covariance matrix is not positive definit therefore the estimation is not 
trustworthy.
Page 56 of 56
http://mc.manuscriptcentral.com/jop
Journal of Psychopharmacology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
2
Supplement 2. Scree plots in the samples from 5 countries. 
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6 Factor 7 Factor 8
Hungarian 7.912 3.695 2.548 1.602 1.033 0.987 0.759 0.56
German 7.208 5.009 2.517 1.853 0.945 0.825 0.646 0.505
Dutch 8.253 3.438 2.432 1.503 1.068 0.824 0.722 0.59
Polish 8.12 3.756 2.79 1.837 0.901 0.774 0.688 0.581
Portugal 6.822 4.158 2.825 1.857 0.979 0.931 0.855 0.708
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